Connect Biopharma Holdings Limited

Contributing Author

Recent Articles by Connect Biopharma Holdings Limited

May-12	Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference CNTB +14.53% CNTB -8.58% GlobeNewswire
May-12	Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update CNTB +14.53% GlobeNewswire
Apr-23	Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis CNTB GlobeNewswire
Mar-31	Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update CNTB -9.66% GlobeNewswire
Mar-30	Connect Biopharma Announces $20.2 Million Private Placement Financing CNTB -15.94% GlobeNewswire
Mar-30	Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study CNTB -15.94% GlobeNewswire
Mar-30	Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD CNTB -15.94% GlobeNewswire
Mar-10	Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting CNTB +5.28% GlobeNewswire
Mar-03	Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference CNTB GlobeNewswire
Feb-19	Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference CNTB GlobeNewswire
Jan-12	Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026 CNTB GlobeNewswire
Nov-24	Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference CNTB GlobeNewswire
Nov-12	Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update CNTB +5.92% GlobeNewswire
Sep-29	Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025 CNTB -16.64% GlobeNewswire
Sep-04	Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025 CNTB -10.55% GlobeNewswire
Sep-03	Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq CNTB -5.69% GlobeNewswire
Aug-27	Connect Biopharma to Present at Two Upcoming Investor Conferences in September CNTB GlobeNewswire
Aug-14	Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide CNTB -8.90% GlobeNewswire
Aug-13	Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update CNTB GlobeNewswire
Jul-22	Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors CNTB +19.00% GlobeNewswire
Jul-21	Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq CNTB +16.28% GlobeNewswire
Jul-18	Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference CNTB -7.53% GlobeNewswire
Jul-17	Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement CNTB +14.81% GlobeNewswire
Jul-09	Connect Biopharma's Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China CNTB GlobeNewswire
Jun-13	Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress CNTB +11.76% GlobeNewswire
Jun-03	Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress CNTB GlobeNewswire
May-28	Connect Biopharma to Present at Two Upcoming Investor Conferences in June CNTB GlobeNewswire
May-20	Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference CNTB +8.12% GlobeNewswire
May-15	Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update CNTB -5.58% GlobeNewswire
May-14	Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD CNTB GlobeNewswire
May-13	Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma CNTB -5.16% GlobeNewswire

Connect Biopharma Holdings Limited

Recent Articles by Connect Biopharma Holdings Limited

Upgrade your Finviz experience